Skip to main content
Erschienen in: Annals of Hematology 9/2017

08.06.2017 | Original Article

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

verfasst von: Oussama Abla, Raul C. Ribeiro, Anna Maria Testi, Pau Montesinos, Ursula Creutzig, Lillian Sung, Giancarlo Di Giuseppe, Derek Stephens, James H. Feusner, Bayard L. Powell, Henrik Hasle, Gertjan J. L. Kaspers, Luciano Dalla-Pozza, Alvaro Lassaletta, Martin S. Tallman, Franco Locatelli, Dirk Reinhardt, Francesco Lo-Coco, Johann Hitzler, Miguel A. Sanz

Erschienen in: Annals of Hematology | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Clinical trials on childhood acute promyelocytic leukemia (APL) report early death (ED) rates of 3–8%, but predictors of thrombohemorrhagic (TH)-ED are not well understood. In a retrospective study, we aimed to determine the incidence and predictors of TH-ED in childhood APL. Data were analyzed from children and adolescents with t(15;17)-positive APL (n = 683) who started treatment with all-trans retinoic acid (ATRA) and chemotherapy in different international studies. Demographic data; initial white blood cell (WBC), peripheral blood (PB) blast, and platelet counts; hemoglobin value; coagulation parameters; morphologic variant (M3 or M3v); and induction details were analyzed. Early death was defined as death occurring within 30 days of presentation. The incidence of ED was 4.7% (32 of 683 patients). Predictors of TH-ED were identified by univariable and multivariable Cox proportional hazard regression analyses (n = 25). In univariable analysis, high WBC (>10 × 109/L) (P < 0.001) and high PB blast (>30 × 109/L) (P < 0.001), M3v (P < 0.01), and black ethnicity (P < 0.001) were independent predictors of TH-ED. In multivariable analysis, high WBC count (P < 0.01) and obesity (i.e., body mass index ≥95th percentile for age) (P = 0.03) were predictors of TH-ED. Initial high WBC counts and obesity are likely predictors of TH-ED in childhood APL. The efficacy of novel drugs for APL-associated coagulopathy or of frontline arsenic trioxide and ATRA combination regimens in reducing ED rates in childhood APL remains to be established.
Literatur
1.
Zurück zum Zitat Ortega JJ, Madero L, Martin G et al (2005) Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol 23(30):7632–7640CrossRefPubMed Ortega JJ, Madero L, Martin G et al (2005) Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol 23(30):7632–7640CrossRefPubMed
2.
Zurück zum Zitat De Botton S, Coiteux V, Chevret S et al (2004) Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 22:1404–1412CrossRefPubMed De Botton S, Coiteux V, Chevret S et al (2004) Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 22:1404–1412CrossRefPubMed
3.
Zurück zum Zitat Testi AM, Biondi A, Lo Coco F et al (2005) GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 106:447–453CrossRefPubMed Testi AM, Biondi A, Lo Coco F et al (2005) GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 106:447–453CrossRefPubMed
4.
Zurück zum Zitat Mann G, Reinhardt D, Ritter J et al (2001) Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 80:417–422CrossRefPubMed Mann G, Reinhardt D, Ritter J et al (2001) Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 80:417–422CrossRefPubMed
5.
Zurück zum Zitat Bally C, Fadlallah J, Leverger G et al (2012) Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. J Clin Oncol 30:1641–1646CrossRefPubMed Bally C, Fadlallah J, Leverger G et al (2012) Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. J Clin Oncol 30:1641–1646CrossRefPubMed
6.
Zurück zum Zitat de la Serna J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402CrossRefPubMed de la Serna J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402CrossRefPubMed
7.
Zurück zum Zitat Rodeghiero F, Avvisati G, Castaman G et al (1990) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 75:2112–2117PubMed Rodeghiero F, Avvisati G, Castaman G et al (1990) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 75:2112–2117PubMed
8.
Zurück zum Zitat Kutny MA, Moser BA, Laumann K et al (2012) FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 59:662–667CrossRefPubMedPubMedCentral Kutny MA, Moser BA, Laumann K et al (2012) FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 59:662–667CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat WHO Multicentre Growth Reference Study Group (2006) WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. World Health Organization, Geneva 312 pages WHO Multicentre Growth Reference Study Group (2006) WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. World Health Organization, Geneva 312 pages
10.
Zurück zum Zitat Testi AM, Foa R, Tomei G, et al. (2010) GIMEMA-AIEOP AIDA protocols for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children: analysis of 247 patients enrolled in two sequential italian multicenter trials. American Society of Hematology 52 Annual Meeting. Orlando, FL. Abstract # 871 Testi AM, Foa R, Tomei G, et al. (2010) GIMEMA-AIEOP AIDA protocols for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children: analysis of 247 patients enrolled in two sequential italian multicenter trials. American Society of Hematology 52 Annual Meeting. Orlando, FL. Abstract # 871
11.
Zurück zum Zitat Sanz MA, Montesinos P, Rayón C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137–5146CrossRefPubMed Sanz MA, Montesinos P, Rayón C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137–5146CrossRefPubMed
12.
Zurück zum Zitat Creutzig U, Zimmermann M, Dworzak M et al (2010) Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol 149:399–409CrossRefPubMed Creutzig U, Zimmermann M, Dworzak M et al (2010) Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol 149:399–409CrossRefPubMed
13.
Zurück zum Zitat Powell BL, Moser B, Stock W et al (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751–3757CrossRefPubMedPubMedCentral Powell BL, Moser B, Stock W et al (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751–3757CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Lie SO, Abrahamsson J, Clausen N et al (2005) Long-term results in children with AML: NOPHO-AML study group—report of three consecutive trials. Leukemia 19:2090–2100CrossRefPubMed Lie SO, Abrahamsson J, Clausen N et al (2005) Long-term results in children with AML: NOPHO-AML study group—report of three consecutive trials. Leukemia 19:2090–2100CrossRefPubMed
15.
Zurück zum Zitat Hasle H, Abrahamsson J, Forestier E et al (2012) Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 120:978–984CrossRefPubMed Hasle H, Abrahamsson J, Forestier E et al (2012) Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 120:978–984CrossRefPubMed
17.
Zurück zum Zitat Breccia M, Mazzarella L, Bagnardi V et al (2012) Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukaemia treated with the AIDA protocols. Blood 119:49–54CrossRefPubMed Breccia M, Mazzarella L, Bagnardi V et al (2012) Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukaemia treated with the AIDA protocols. Blood 119:49–54CrossRefPubMed
18.
Zurück zum Zitat Feusner J, Kim H, Gregory J et al (2006) Obesity in newly diagnosed childhood acute promyelocytic leukaemia. Blood 108:4494 (ASH Annual Meeting Abstracts) Feusner J, Kim H, Gregory J et al (2006) Obesity in newly diagnosed childhood acute promyelocytic leukaemia. Blood 108:4494 (ASH Annual Meeting Abstracts)
19.
Zurück zum Zitat Lee JH, Rademaker AW, Powell BL, et al. Obesity does not affect the recurrence free survival rates in children less than 20 years of age in acute promyelocytic leukemia (APL). American Society of Hematology 56th Annual Meeting, 2014; Blood, 124:957. Lee JH, Rademaker AW, Powell BL, et al. Obesity does not affect the recurrence free survival rates in children less than 20 years of age in acute promyelocytic leukemia (APL). American Society of Hematology 56th Annual Meeting, 2014; Blood, 124:957.
20.
Zurück zum Zitat Orgel E, Genkinger JM, Aggrawal D et al (2016) Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr 103(3):808–817CrossRefPubMed Orgel E, Genkinger JM, Aggrawal D et al (2016) Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr 103(3):808–817CrossRefPubMed
21.
Zurück zum Zitat Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA (2005) Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293:203–211CrossRefPubMed Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA (2005) Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293:203–211CrossRefPubMed
22.
Zurück zum Zitat Pezzini A, Grassi M, Paciaroni M et al (2013) Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy. Stroke 44:1584–1589CrossRefPubMed Pezzini A, Grassi M, Paciaroni M et al (2013) Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy. Stroke 44:1584–1589CrossRefPubMed
23.
Zurück zum Zitat Stazzullo P, D’Elia L, Cairella G et al (2010) Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 41(5):e418–e426CrossRef Stazzullo P, D’Elia L, Cairella G et al (2010) Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 41(5):e418–e426CrossRef
24.
Zurück zum Zitat Siklar Z, Ocal G, Berberoglu M et al (2012) Evaluation of hypercoagulability in obese children with thrombin generation test and microparticle release: effect of metabolic parameters. Clin Appl Thromb Hemost 17:585–589CrossRef Siklar Z, Ocal G, Berberoglu M et al (2012) Evaluation of hypercoagulability in obese children with thrombin generation test and microparticle release: effect of metabolic parameters. Clin Appl Thromb Hemost 17:585–589CrossRef
25.
Zurück zum Zitat Ayer G, Song K, Steinbeck D, Celermajer S, Freedman SB (2010) Increased tissue factor activity in monocytes from obese young adults. Clin Exp Pharmacol Physiol 37:1049–1054CrossRefPubMed Ayer G, Song K, Steinbeck D, Celermajer S, Freedman SB (2010) Increased tissue factor activity in monocytes from obese young adults. Clin Exp Pharmacol Physiol 37:1049–1054CrossRefPubMed
26.
Zurück zum Zitat Vahdat L, Maslak P, Miller WH Jr et al (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukaemia: impact of leukocytosis, low-dose chemotherapy, PML-RARa isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843–3849PubMed Vahdat L, Maslak P, Miller WH Jr et al (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukaemia: impact of leukocytosis, low-dose chemotherapy, PML-RARa isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843–3849PubMed
27.
Zurück zum Zitat Sanz MA, Lo Coco F, Martin G et al (2000) Definition of relapse risk and role of non anthracycline drugs for consolidation in patients with acute promyelocytic leukaemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed Sanz MA, Lo Coco F, Martin G et al (2000) Definition of relapse risk and role of non anthracycline drugs for consolidation in patients with acute promyelocytic leukaemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed
28.
Zurück zum Zitat Stein E, McMahon B, Kwaan H et al (2009) The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 22:153–163CrossRefPubMed Stein E, McMahon B, Kwaan H et al (2009) The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 22:153–163CrossRefPubMed
29.
Zurück zum Zitat Mckenna RW, Parkin J, Bloomfield CD et al (1982) Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol 50:201–214CrossRefPubMed Mckenna RW, Parkin J, Bloomfield CD et al (1982) Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol 50:201–214CrossRefPubMed
30.
Zurück zum Zitat Gale RF, Hills R, Pizey AR et al (2005) Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106:3768–3776CrossRefPubMed Gale RF, Hills R, Pizey AR et al (2005) Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106:3768–3776CrossRefPubMed
31.
Zurück zum Zitat LoCoco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–121CrossRef LoCoco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–121CrossRef
Metadaten
Titel
Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy
verfasst von
Oussama Abla
Raul C. Ribeiro
Anna Maria Testi
Pau Montesinos
Ursula Creutzig
Lillian Sung
Giancarlo Di Giuseppe
Derek Stephens
James H. Feusner
Bayard L. Powell
Henrik Hasle
Gertjan J. L. Kaspers
Luciano Dalla-Pozza
Alvaro Lassaletta
Martin S. Tallman
Franco Locatelli
Dirk Reinhardt
Francesco Lo-Coco
Johann Hitzler
Miguel A. Sanz
Publikationsdatum
08.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3042-6

Weitere Artikel der Ausgabe 9/2017

Annals of Hematology 9/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.